Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode

Asian Journal of Psychiatry

Volumn 6, Issue 1, 2013, Pages 29-34

  Jangid, Purushottam ^a   Malik, Prerna ^a   Singh, Priti ^a   Sharma, Minakshi ^b   Gulia, Anil kumar D ^a,c  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAHARSHI DAYANAND UNIVERSITY   (India)

^c BPS Government Medical College   (India)

Author keywords

CGI; Depression; Fluoxetine; HAM D; L 5 HTP; L 5 Hydroxytryptophan

Indexed keywords

5 HYDROXYTRYPTOPHAN; FLUOXETINE;

ADULT; ANOREXIA; ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

5-HYDROXYTRYPTOPHAN; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873167541     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2012.05.011     Document Type: Article

References (34)

1. Angst J., Woggon B., Schoepf J. The treatment of depression with l-5-hydroxytryptophan versus imipramine. Archiv fur Psychiatrie und Nervenkrankheiten 1977, 224:175-186.
2. Birdsall T.C. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Alternative Medicine Review 1998, 3:271-280.
3. Blier P., Ward H.E., Tremblay P., Laberge L., Hebert C., Bergeron R. Combination of antidepressant medication from treatment initiation for major depressive disorder: a double-blind randomized study. American Journal of Psychiatry 2010, 167(3):281-288.
4. Byerley W.F., Judd L.L., Reimherr F.W., Grosser B.I. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 1987, 7:127-137.
5. Coppen A., Eccleston E.G., Peet M. Total and free tryptophan concentration in the plasma of depressive patients. Lancet 1973, 2:60-63.
6. Cowen P.J., Parry-Billings M., Newsholme E.A. Decreased plasma tryptophan levels in major depression. Journal of Affective Disorders 1989, 16:27-31.
7. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry 1990, 47:411-418.
8. Fujiwara J., Otsuki S. Subtype of affective psychoses classified by response on amine precursors and monoamine metabolism. Psychiatry and Clinical Neurosciences 1974, 28:93-100. http://en.wikipedia.org/wiki/PubMed_Identifier16.
9. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology 1976, Department of Health Education and Welfare, DHEW Publication No. (ADM): 76-338.
10. Hamilton M. Rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960, 23:56-62.
11. Hechbech J., Hansen H.E., Amdisen A. Chronic renal lesions following long term treatment with lithium. Kidney International 1977, 12:205-213.
12. Joyce P.R. Epidemiology of Mood Disorders. New Oxford Textbook of Psychiatry 2009, 645-650. Oxford University Press Inc., New York. M.G. Gelder, N.C. Andreason, J.J. Loper-Ibor, J.R. Geddes (Eds.).
13. Lam R.W., Zis A.P., Grewal A., Delgado P.L., Charney D.S., Krystal J.H. Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Archives of General Psychiatry 1996, 53:41-44.
14. Lonnqvist J., Sintonen H., Syvalahti E., Appelberg B., Koskinen T., Mannikko T., Mehtonen O.P., Naarala M., Sihvo S., Auvinen J., Pitkanen H. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatrica Scandinavica 1994, 89(6):363-369.
15. Magnussen I., Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered l-5-hydroxytryptophan in steady state. Acta Pharmacologica et Toxicologica 1980, 46:257-262.
16. Nakajima T., Kudo Y., Kaneko Z. Clinical evaluation of 5-hydroxy-l-tryptophan as an antidepressant drug. Folia Psychiatrica et Neurologica Japonica 1978, 32(2):223-230.
17. Nandi D.N., Ajmany S. Psychiatric disorders in rural community in West Bengal: an epidemiological study. International Journal of Psychiatry 1975, 17:87-92.
18. Neumeister A., Turner E.H., Matthews J.R., Postolache T.T., Barnett R.L., Rauh M., Vetticad R.G., Kasper S., Rosenthal N.E. Effects of tryptophan depletion vs. catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Archives of General Psychiatry 1998, 55:524-530.
19. Neumeister A. Tryptophan depletion, serotonin, and depression: where do we stand?. Psychopharmacology Bulletin 2003, 37:99-115.
20. Nolen W.A., Van de Putte J.J., Dijken W.A., Kamp J.S., Blansjaar B.A., Kramer H.J., Haffmans J. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatrica Scandinavica 1988, 78(6):668-675.
21. Nolen W.A., Van de Putte J.J., Dijken W.A., Kamp J.S. l-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. British Journal of Psychiatry 1985, 147:16-22.
22. O'Neil M.F., Moore N.A. Animal models of depression: are there any?. Human Psychopharmacology 2003, 18:239-254.
23. Poldinger W., Calencline B., Schwarz W. A functional dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991, 24:53-81.
24. Quitkin F.M., Rabkin J.G. Methodological problems in studies of depressive disorders: utility of discontinuations design. Journal of Clinical Psychopharmacology 1981, 1:283288.
25. Quitkin F.M., Rabkin J.G., Ross D., McGrath P.J. Duration of antidepressant drug treatment. Archives of General Psychiatry 1984, 41:238-245.
26. Sano I. l-5-Hydroxytryptophan-(l-5-HTP) therapy. Folia Psychiatrica et Neurologica Japonica 1972, 26:7-17.
27. Sethi B.B., Gupta S.C. A psychiatric survey of 500 rural families. International Journal of Psychiatry 1972, 14:183-196.
28. Shaw K., Turner J., Del Mar C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Australian and New Zealand Journal of Psychiatry 2002, 36(4):488-491.
29. Thomson J., Rankin H., Ashcroft G.W., Yates C.M., McQueen J.K., Cummings S.W. The treatment of depression in general practice: a comparison of l-tryptophan, amitryptiline, and a combination of l-tryptophan and amitryptiline with placebo. Psychological Medicine 1982, 12:741-751.
30. Van Hiele L.J. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with therapy-resistant depressions. Neuropsychobiology 1980, 6:230-240.
31. Van Praag H.M. Central seroton. Biological Psychiatry Today 1979, 485-498. Elsevier, Amsterdam. its relation to depression vulnerability, P. depression, J. Obiols, C. Ballus, E. Gastpar, J. Pujol (Eds.).
32. Van Praag H.M. Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacology Bulletin 1984, 20:599-602.
33. Varma V.K., Das K. Mental illness in India: epidemiology, manifestations and outcome. Indian J Social Psychiatry 1995, 11:16-25.
34. Zmilacher K., Battegay R., Gastpar M. l-5-Hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988, 20:28-35.